Last week, in recognition of #RareDiseaseDay, we gathered to hear from our very own Alain Lamontagne and Karen Wagenbrenner. Alain and Karen shared their personal connection to #Rettsyndrome, a rare neurodevelopmental disease, and discussed the importance of raising awareness for individuals, families and caregivers impacted by rare diseases. We also took the opportunity to join NORD’s #ShowYourStripes campaign in support of the many faces of rare disease!
Taysha Gene Therapies
Biotechnology
Dallas, TX 18,655 followers
Taysha Gene Therapies is focused on advancing AAV-based gene therapies for severe monogenic diseases of the CNS.
About us
Taysha Gene Therapies is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside.
- Website
-
http://www.tayshagtx.com
External link for Taysha Gene Therapies
- Industry
- Biotechnology
- Company size
- 51-200 employees
- Headquarters
- Dallas, TX
- Type
- Public Company
- Founded
- 2020
- Specialties
- Gene Therapy, Central Nervous System, and Molecular Biology
Locations
-
Primary
Dallas, TX, US
Employees at Taysha Gene Therapies
Updates
-
Today, we announced our full-year 2024 earnings and provided a corporate update. We are pleased with the progress we’ve made to advance our TSHA-102 #genetherapy program in clinical evaluation for #Rettsyndrome and look forward to the milestones anticipated this year. Learn more: https://lnkd.in/eVBNVHn3
-
-
The countdown to Rare Disease Day is on! Recognized on the last day of February each year, #RareDiseaseDay is a global initiative to raise awareness and generate support for everyone on a rare medical journey. Learn more about Rare Disease Day and how to get involved by visiting https://lnkd.in/etGpncj.
-
-
Next week, we will announce our full-year 2024 earnings and provide a corporate update. For more information, visit: https://lnkd.in/e_GEH-GJ
-
-
Today, we reported our third quarter 2024 earnings and provided a corporate update. We are encouraged by the recent progress we’ve made across our lead TSHA-102 #genetherapy program in clinical evaluation for #Rettsyndrome and remain focused on execution as we prepare for what we expect to be an impactful year ahead. Read the release to learn more: https://lnkd.in/gTAyNXHv
-
-
Next week, we will announce our third quarter 2024 earnings and provide a corporate update. For more information, visit: https://lnkd.in/gairgb2G
-
-
Taysha is pleased to support the International Rett Syndrome Foundation’s Strollathon events to help fundraise, advocate and accelerate research for #Rettsyndrome. Learn more: https://lnkd.in/ggTwZydy #RettSyndromeAwarenessMonth
-
-
-
-
-
+2
-
-
In recognition of Rett Syndrome Awareness Month, the Taysha team gathered for a viewing of Magnolia’s Hope, a documentary following the Tesler family’s journey with #RettSyndrome. We had the privilege of speaking with AJ Tesler, the film’s documentarian whose daughter lives with Rett syndrome. Thank you, AJ, for sharing your family’s story and for your continued dedication to raising awareness of Rett syndrome. #RettSyndromeAwarenessMonth
-
-
We look forward to presenting biodistribution data evaluating AAV9 #genetherapy delivery across five non-human primate studies at the #ESGCT2024 Annual Congress. These findings support the potential of intrathecal administration as an effective, safe and minimally invasive approach to deliver AAV-based gene therapies designed to treat CNS diseases in both children and adults. Learn more about our upcoming presentation: https://lnkd.in/eHTAikP8
-
-
October 1 marks the start of Rett Syndrome Awareness Month, a time dedicated to raising awareness of Rett syndrome to support patients and families living with the disease. Taysha is proud to help raise awareness of this rare neurodevelopmental disorder as we continue on our mission to bring a #genetherapy to all patients and families living with #Rettsyndrome. #RettSyndromeAwarenessMonth
-